Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models

Ilg, MM; Mateus, M; Stebbeds, WJ; Milenkovic, U; Christopher, N; Muneer, A; Albersen, M; ... Cellek, S; + view all Ilg, MM; Mateus, M; Stebbeds, WJ; Milenkovic, U; Christopher, N; Muneer, A; Albersen, M; Ralph, DJ; Cellek, S; - view fewer (2018) Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models. European Urology 10.1016/j.eururo.2018.10.014 . (In press). Green open access

https://ift.tt/2DedeFh